HP
DAWN

Harbourvest Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

Harbourvest Partners’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,388
Closed -$226K – 70
2021
Q4 		$226K Buy
+13,388
New +$275K 0.03% 61

Other funds holding DAWN

CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harbourvest Partners's DAWN Position: Q1 2022 in Review

Harbourvest Partners sold out of Day One Biopharmaceuticals (DAWN) in Q1 2022, closing a stake of 13,388 shares — an estimated $226K sold.

Harbourvest Partners first reported a position in DAWN in Q4 2021 and held it in 1 quarter. The position peaked at $226K in Q4 2021. 66 funds tracked by Wall St. Rank hold DAWN as of Q1 2022.

  • Harbourvest Partners reported no remaining Day One Biopharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Harbourvest Partners sold 13,388 Day One Biopharmaceuticals shares in Q1 2022, an estimated $226K.
  • Harbourvest Partners first reported a position in Day One Biopharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Harbourvest Partners's Day One Biopharmaceuticals position peaked at $226K in Q4 2021.
  • 66 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2022.

Based on Harbourvest Partners's 13F filing for Q1 2022, filed 13 May 2022.